Case series of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors

Kana Hayashi; Kotaro Tokui; Minehiko Inomata; Kenji Azechi; Isami Mizushima; Naoki Takata; Chihiro Taka; Seisuke Okazawa; Kenta Kambara; Shingo Imanishi; Toshiro Miwa; Ryuji Hayashi; Shoko Matsui; Satoshi Nomura; Kazuyuki Tobe

doi:10.21873/invivo.12428

Case series of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors

Kana Hayashi, Kotaro Tokui, Minehiko Inomata^*, Kenji Azechi, Isami Mizushima, Naoki Takata, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Satoshi Nomura, Kazuyuki Tobe

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Aim: We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nabpaclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter. Conclusion: Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung.

Original language	English
Pages (from-to)	1687-1692
Number of pages	6
Journal	In Vivo
Volume	35
Issue number	3
DOIs	https://doi.org/10.21873/invivo.12428
State	Published - 2021/05

Keywords

Immune checkpoint inhibitor
Pembrolizumab
Pleomorphic carcinoma
Sarcomatoid carcinoma

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
Pharmacology
Cancer Research

Access to Document

10.21873/invivo.12428

Cite this

@article{439b3e7c16184253ad5a73fe814eb60e,

title = "Case series of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors",

abstract = "Aim: We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nabpaclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter. Conclusion: Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung.",

keywords = "Immune checkpoint inhibitor, Pembrolizumab, Pleomorphic carcinoma, Sarcomatoid carcinoma",

author = "Kana Hayashi and Kotaro Tokui and Minehiko Inomata and Kenji Azechi and Isami Mizushima and Naoki Takata and Chihiro Taka and Seisuke Okazawa and Kenta Kambara and Shingo Imanishi and Toshiro Miwa and Ryuji Hayashi and Shoko Matsui and Satoshi Nomura and Kazuyuki Tobe",

year = "2021",

month = may,

doi = "10.21873/invivo.12428",

language = "英語",

volume = "35",

pages = "1687--1692",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "3",

}

TY - JOUR

T1 - Case series of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors

AU - Hayashi, Kana

AU - Tokui, Kotaro

AU - Inomata, Minehiko

AU - Azechi, Kenji

AU - Mizushima, Isami

AU - Takata, Naoki

AU - Taka, Chihiro

AU - Okazawa, Seisuke

AU - Kambara, Kenta

AU - Imanishi, Shingo

AU - Miwa, Toshiro

AU - Hayashi, Ryuji

AU - Matsui, Shoko

AU - Nomura, Satoshi

AU - Tobe, Kazuyuki

PY - 2021/5

Y1 - 2021/5

N2 - Aim: We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nabpaclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter. Conclusion: Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung.

AB - Aim: We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nabpaclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter. Conclusion: Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung.

KW - Immune checkpoint inhibitor

KW - Pembrolizumab

KW - Pleomorphic carcinoma

KW - Sarcomatoid carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85105066167&partnerID=8YFLogxK

U2 - 10.21873/invivo.12428

DO - 10.21873/invivo.12428

M3 - 学術論文

C2 - 33910853

AN - SCOPUS:85105066167

SN - 0258-851X

VL - 35

SP - 1687

EP - 1692

JO - In Vivo

JF - In Vivo

IS - 3

ER -

Case series of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this